Genetic metabolic polymorphisms and the risk of cancer: a review of the literature

References

• Abe S., Makimura S., Ogura S., Nakajma Y. Pulmonary drug-metabolizing enzyme in alveolar macrophages in relation to cigarette smoking. Japanese Journal of Medicine 1990; 29: 164–167
   PubMedGoogle Scholar
• Agundez J. a. G., Martinez C, Ladero J. M., Ledesma M. C., Ramos J. M., Martin R., Rooriquez A., Jara C., Benitez J. Debrisoquine oxidation genotype and susceptibility to lung cancer. Clinical Pharmacology & Therapevtics 1994; 55: 10–14
   PubMed Web of Science ®Google Scholar
• Agundez J. A. G., Ladero J. M., Olivera M., Abldua R., Roman J. M., Benitez J. Genetic analysis of the arylamine, N-acetyltransferase polymorphism in breast cancer patients. Oncology 1995; 52: 7–11
   PubMed Web of Science ®Google Scholar
• Alexandre A. K., Ingelman-Sundberg M., Sodeqard J., Tornljng G., Ramnug A. Genetic susceptibility to lung cancer with special emphasis on CYPlAl and GSTMI: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 1994; 15: 1785–1790
   PubMed Web of Science ®Google Scholar
• Ambrosone C. B., Freudenheim J. L., Graham S., Marshall J. R., Vena J. E., Brasure J. E., Laughun R., Nemoto T., Michalek A. M., Harrington A., Ford T. D., Shields P. G. Cytochrome P4501A1 and glutathione Stransferase (M1genetic polymorphisms and postmenopausal breast cancer risk. Cancer Research 1995; 55: 3483–3485
   PubMed Web of Science ®Google Scholar
• Amos C. I., Caporaso N. E., Weston A. Host factors in lung cancer risk: a review of interdisciplinary studies. Cancer Epidemiology, Biomarkers and Prevention 1992; 1: 505–513
   PubMed Web of Science ®Google Scholar
• Ayesh R., Idle J. R., Ritchie J. C., Crothers M. J., Hetzel M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984; 312: 169–170
   PubMed Web of Science ®Google Scholar
• Bell D. A., Taylor J. A., Paulson D. R, Robertson C. N., Mohler J. L., Lucer G. W. Genetic risk and carcinogenesis exposure: a common inheried defect of the carcinogen-metabolism gene glutathione Stransferase M1 (GSTM1that increases susceptibillty to bladder cancer. Journal of the National Cancer Institute 1993; 85: 1159–1164
   PubMed Web of Science ®Google Scholar
• Benitez J.L., Adero J. M., Fernandez-Gundin M. J., Llerena A., Cobaleda J., Martinez C, Munoz J. J., Vargas E., Prados J., Gonzalez-Rozas F., Rodriguez-Molina J., Uson A. C. Polymorphic oxidation of debrisoquine in bladder cancer. Annals of Medicine 1990; 22: 157–160
   PubMed Web of Science ®Google Scholar
• Benitez J., Ladero J. M., Jara C., Carrillo J. A., Cobaleda J., Llerena A., Vargas E., Munoz J. J. Polymorphic oxidation of debrisoquine in lung cancer patients. European Journal of Cancer 1991; 27: 158–161
   PubMed Web of Science ®Google Scholar
• Board P., Coggan M., Johnston P., Ross V., Suzuki T. G. W. Genetic heterogeneity of the human glutathione transferase: a complex of gene families. Pharmacological Therapy 1990; 48: 357–369
   PubMed Web of Science ®Google Scholar
• Brockmoller J., Kerb R., Drakoulis N., Nitz M., Roots I. Genotype and phenotype of glutathione Stransferase Class μ and ψ in lung cancer patients and controls. Cancer Research 1993; 53: 1004–1011
   PubMed Web of Science ®Google Scholar
• Brockmoller J., Kerb R., Drakoulis N., Staffelot B., Roots I. Glutathione Stransferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a casecontrol study. Cancer Research 1994; 54: 4103–4111
   PubMed Web of Science ®Google Scholar
• Brosen K., Gram L. F., Haghfelt T., Bertlisson L. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacology and Toxicology 1987; 60: 312–314
   PubMedGoogle Scholar
• Buchert E. T., Woosley R. L., Swain S. M., Oliver, Coughlin S. J. S. S., Pickle L., Trock B., Riegel A. T. Relationship of CYP2D6 (debrisoquine hydroxylasegenotype to breast cancer susceptibility. Pharmacogenetics 1993; 3: 322–327
   PubMedGoogle Scholar
• Bulovskaya L. N., Krupkin R. G., Bochina T. A., Shipkova A. A., Pavlova M. V. Acetylator phenotype in patients with breast cancer. Oncology 1978; 35: 185–188
   PubMed Web of Science ®Google Scholar
• Burgess E. J., Trafford J. A. P. Acetylator phenotype in patients with lung carcinoma—a negative report. European Journal of Respiratory Diseases 1985; 67: 17–19
   PubMedGoogle Scholar
• Caporaso N., Hayes R. B., Dosemeci M., Hoover R., Ayeshi R., Hetzel M., Idle J. Lung cancer risk, occupational exposure, and debrisoquine metabolic phenotype. Cancer Research 1989; 49: 3675–3679
   PubMed Web of Science ®Google Scholar
• Caporaso N., Tucker M. A., Hoover R. N., Hayes R. B., Pickle L. W., Issaq H. L., Muschik G. M., Green-Gallo L, Buivys D., Aisner S., Resau J. H., Trump B. F., Tolerud D., Wetson A., Harris C. C. Lung cancer and debrisoquine metabolic phenotype. Journal of the National Cancer Institute 1990; 82: 1264–1272
   PubMed Web of Science ®Google Scholar
• Cartwright R. A., Rogers H. J., Barham-Hall D., Glashan R. W., Ahmad R. A., Higgins E., Kahn M. A. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982; 2: 842–845
   PubMed Web of Science ®Google Scholar
• Cartwright R. A., Phiup P. A., Rogers H. J., Glashan R. W. Genetically determined debrisoquine oxidation capaclty in bladder cancer. Carcinogenesis 1984; 5: 1191–1192
   PubMed Web of Science ®Google Scholar
• Cornfield J. A statistical problem arising from retrospective studies. Proceedings of the Third Berkeley Symposium. University of California Press, Berkeley 1956; IV: 133–148
   Google Scholar
• Cosma G. N., Crofts F., Currie D., Wirgin I., Tomolo P., Garte S. J. Racial differences in restriction fragment length polymorphisms and messenger RNA inducibility of the human CYPlAl gene. Cancer Epidemiology, Biomarkers and Prevention 1993; 2: 53–57
   PubMed Web of Science ®Google Scholar
• Cresfl C. L., Penman B. W., Gelboin H. V., Gonzalez F. J. A tobaccclsmoke derived nitrosamine, 4(methylnitrosamino)-l-(3-pyridyl)-1. butanone, is activated by multiple human P450s including the polymorphic cytocrome P-4502D6. Carcinogenesis 1991; 12: 1197–1201
   PubMed Web of Science ®Google Scholar
• Crofts F., Cosma G., Currie D., Taioli E., Toniolo P., Garte S. J. A novel CYPlAl gene polymorphism in Africaw-Americans. Carcinogenesis 1993; 14: 1729–1731, [published erratum appears in Carcinogensis (1993 14 (121, 2652]
   PubMed Web of Science ®Google Scholar
• Crofts F., Taioli E., Trachman J., Cosma G. N., Currie D., Toniolo P., GarteE S. Functional significance of different human CYPlAl genotypes. Carcinogenesis 1994; 15: 2961–2963
   PubMed Web of Science ®Google Scholar
• Daly A. K., Thomas D. J., Cooper J., Pearson W. R., Neal D. E., Idle J. R. Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer. British Medical Journal 1993; 307: 481–482
   PubMed Web of Science ®Google Scholar
• Duche J. C., Joanne C., Barre J., De Cremoux H., Dalphin J. C., Depierre A., Brochard P., Tillement J. P., Bechtel P. Lack of a relationship between the polymorphism of debrisoquinone oxidation and lung cancer. British Journal of Clinical Pharmacology 1991; 31: 533–536
   PubMed Web of Science ®Google Scholar
• Emery A. E., Anand R., Dandord N., Duncan W., Paton L. Aryl hydrocarboMydroxylase inducibility in patients with cancer. Lancet 1978; 1: 470–472
   PubMed Web of Science ®Google Scholar
• Evans D. A. P. N-Acetyltransferase. Pharmacological Therapy 1989; 42: 157–234
   PubMed Web of Science ®Google Scholar
• Evans D. A. P., White T. A. Human acetylation polymorphism. Journal of laboratory and Clinical Medicine 1964; 63: 394–403
   PubMed Web of Science ®Google Scholar
• Evans D. A. P., Manley K. A., McKusick V. A. Genetic control of isoniazid metabolism in man. British Medical Journal 1960; 2: 485–491
   PubMed Web of Science ®Google Scholar
• Fleiss J. L., Tytun A., Uray H. K. A simple approximation for calculating sample sizes for comparing independent proportions. Biometncs 1980; 36: 343–346
   PubMed Web of Science ®Google Scholar
• Gahmberg C. G., Sekki A., Kosunen T. U., Holsti L. R., Makela O. Induction of aryl hydrocarbon hydroxylase activity and pulmonary carcinoma. International Journal of Cancer 1979; 23: 302–305
   PubMed Web of Science ®Google Scholar
• Garte S. J., Trachman J., Crofts F., Tonion P., Buxbaum J., Bayo S., Taoli E. Distribution of composite CYP1A1 genotypes in African-Americans, Africans and Caucasians. Human Heridity 1996; 46: 121–127
   PubMed Web of Science ®Google Scholar
• Grant D. M. Molecular genetics of the N-acetyttransferase. Pharmacogenetics 1993; 3: 45–50
   PubMedGoogle Scholar
• Guirgis H. A., Lynch H. T., Mate T., Harris R. E., Wells I., Caha L., Anderson J., Maloney K., Rankin L. Aryl-hydrocarbon hydroxylase activity in lymphocytes from lung patients and normal controls. Oncology 1976; 33: 105–198
   PubMed Web of Science ®Google Scholar
• Hamada G. S., Sugimura H., Suzuki J., Nagura K., Kiyokawa E., Iwase T., Tanaka M., Takahashi T., Watanabe S., Kino I., Tsugane S. The heme-binding region polymorphism of cytochrome P4501A1 (CYP1A1), rather than the Rsal polymorphism of P450IIE1 (CYPIIE1), is associated with lung cancer in Rio de Janeiro. Cancer Epidemiology, Biomarkers and Prevention 1995; 4: 917–918
   Web of Science ®Google Scholar
• Hanke J., Krajewska B. Acetylation phenotypes and bladder cancer. Journal of Occupational Medicine 1990; 32: 917–918
   PubMedGoogle Scholar
• Hanssen H. P., Agarwal D. P., Goedde H. W., Bucher H., Huland H., Brachmann W., Ovenback R. Association of Nacetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a North German population. European Urology 1985; 11: 263–266
   PubMed Web of Science ®Google Scholar
• Harada S., Misawa S., Nakamura T, Tanaka N., Ueno E., Mutzum N. Detection of GST1 gene deletion by polymerase chain reaction and its possible correlation with stomach cancer in Japanese. Human Genetics 1992; 90: 62–44
   PubMed Web of Science ®Google Scholar
• Hayashi S., Watanabe J., Kawajiri K. High susceptibillty to lung cancer analyzed in terms of combined genotypes of CYP1A1 and Mu-class glutathione S-transferase genes. Japanese Journal of Cancer Research 1992; 83: 866–470
   PubMedGoogle Scholar
• Hayes R. B. B.I. W., Rothman N., Broly F., Caporaso N., Feng P., You X., Yin S., Woosley R. L., Meyer U. A. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 1993; 14: 675–678
   PubMed Web of Science ®Google Scholar
• Hearse D. J., Weber W. W. Multiple N-acetyltransferase and drug metabolism. Biochemical Journal 1973; 132: 519–526
   PubMed Web of Science ®Google Scholar
• Heckbert S. R., Weiss N. S., Hornung S. K., Eaton D. L., Motulsky A. G. Glutathione Stransferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. Journal of the National Cancer Institute 1992; 84: 414–422
   PubMed Web of Science ®Google Scholar
• Heim M. H., Mayer U. A. Genetyc polymorphism of debrisoquine oxidation: restriction fragment analysis and allelespecific amplification of mutant alleles of CYP2D6. Methods in Enzymology 1991; 206: 173–183
   PubMed Web of Science ®Google Scholar
• Hirvonen A., Husgafvel-Pursiainen K., Karjalainen A., Anttila S., Vainio H. Point-mutational Mspl and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiology, Biomarkers and Prevention 1992; 1: 485–489
   PubMed Web of Science ®Google Scholar
• Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Pelkonen O., Vaino H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 1993a; 3: 19–27
   PubMedGoogle Scholar
• Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Vainio H. Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer. Environmental Health Perspectives 1993b; 3: 109–112
   Google Scholar
• Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 1993c; 14: 1479–1481
   PubMed Web of Science ®Google Scholar
• Horai Y., Fujita K., Ishzaki T. Genetically determined N-acetylation and oxidation capacities in Japanese patients with nonoccupational urinary bladder cancer. European Journal of Clinical Pharmacology 1989; 37: 581–587
   PubMed Web of Science ®Google Scholar
• Horsmans Y., Desager J. P., Harvengt C. Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?. Biomedicine & Pharmacotherapy 1991; 45: 359–362
   PubMed Web of Science ®Google Scholar
• Idle J. R., Mahgoub A., Lancaster R., Smith R. L. Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sciences 1978; 22: 979–984
   PubMed Web of Science ®Google Scholar
• Ilett K. F., David B. M., Detchon P., Castleden W. M., Kwa R. Acetylator phenotype in colorectal carcinoma. Cancer Research 1987; 47: 1466–1469
   PubMed Web of Science ®Google Scholar
• Ilett K. F., Detchon P., Ingram D., Castelden W. M. Acetylator phenotype is not associated with breast cancer. Cancer Research 1990; 50: 6649–6651
   PubMed Web of Science ®Google Scholar
• Jaiswal A. K., Gonzales F. J., Nebert D. W. Human P1–450 gene sequence and correlation of mRNA with genetic differences in benzo(a)pyrene metabolism. Nucleic Acids Research 1985; 13: 4503–4520
   PubMed Web of Science ®Google Scholar
• Kadlubar F. F., Butler M. A., Kadelik K. R., Chou H. C., Lang N. P. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environmental Health Perspectives 1992; 98: 69–74
   PubMed Web of Science ®Google Scholar
• Kaisary A., Smith P., Jaczq E., McAllister G. R., Wilkinson C. B., Ray W. A., Branch R. A. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Research 1987; 47: 5488–5493
   PubMed Web of Science ®Google Scholar
• Karakaya A. E., Cok I., Sardas S., Gogus O., Sardas O. S. Wetyltransferase phenotype of patients with bladder cancer. Human Toxicology 1986; 5: 333–335
   PubMedGoogle Scholar
• Karki N. T., Pokela R., Nuutinen L., Pelkonen O. Aryl hydrocarbon hydroxylase in lymphocytes and lung tissue from lung cancer patients and controls. International Journal of Cancer 1987; 39: 565–570
   PubMed Web of Science ®Google Scholar
• Katoh T, Inatomi H., Nagaoka A., Sugta A. Cytochrome P4501A1 gene polymorphism and homozygous deletion of the glutathione S-transferase M1 gene in urothelial cancer patients. Carcinogenesis 1995; 16: 655–657
   PubMed Web of Science ®Google Scholar
• Kawajiri K., Fuji-Kuriyama Y. P450 and human cancer. Japanese Journal of Cancer Research 1991; 82: 1325–1335
   PubMedGoogle Scholar
• Kawajiri K., Nakachi K., Imai K., Yoshi A, Shinoda N., Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450lA1 gene. FEBS Leften 1990; 263: 131–133
   PubMed Web of Science ®Google Scholar
• Kellerman G., Shaw C. R., Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. New England Journal of Medicine 1973; 289: 934–937
   PubMed Web of Science ®Google Scholar
• Kelsey K. T., Wiencke J. K., Spitz M. R. A racespecific genetic polymorphism in the CYP1A1 gene is not associated with lung cancer in African Americans. Carcinogenesis 1994; 15: 1121–1124
   PubMed Web of Science ®Google Scholar
• Kihara M., Kihara M., Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis 1994; 15: 415–418
   PubMed Web of Science ®Google Scholar
• Kouri R. E., McKinney C. E., Slomiany D. J., Snodgrass D. R., Wray N. P., McLmore T. L. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analysed in cryopresetved lymphocytes. Cancer Research 1982; 42: 5030–4037
   PubMed Web of Science ®Google Scholar
• Ladero J. M., Kwok C. K., Jara C., Fernandez L., Silm A. M., Tapia D., Uson A. C. Hepatic acetylator phenotype in bladder cancer patients. Annals of Clinical Research 1985; 17: 97–99
   Google Scholar
• Hero J. M., Fernandez L., Palmeiro R., Munoz J. J., Jara C., Lazaro C., Perez-Manga G. Hepatic acetylation polymorphism in breast cancer patients. Oncology 1987; 44: 341–344
   PubMed Web of Science ®Google Scholar
• Ladero J. M., Gonzales J. F., Benitez J., Vargas E., Fernandez M. J., Baki W., Diaz-Rubio M. Acetylator polymorphism in human colorectal carcinoma. Cancer Research 1991a; 51: 2098–2100
   PubMed Web of Science ®Google Scholar
• Ladero J. M., Benitez J., Jara C., Llerena A., Valdivielso M. J., Munoz J. J., Vargas E. Polymorphic oxidation of debrisoquine in women with breast cancer. Oncology 1991b; 48: 107–110
   PubMed Web of Science ®Google Scholar
• Lafuente A., Puliol F., Carretero P., Perez Villa J., Cuchi A. Human glutathione S-transferase μ (GSTμdeficiency as a marker for susceptibility to bladder and larynx cancer among patients. Cancer Letters 1993; 68: 49–54
   PubMed Web of Science ®Google Scholar
• Lang N. P., Chu D. Z. J., Hunter C. F., Kendall D. C., Flammang T. J., Kadlubar F. F. Role of aromatic amine acetyltransferase in human colorectal cancer. Archives of Surgery 1986; 121: 1259–1261
   PubMed Web of Science ®Google Scholar
• Law M. R., Hetzel M. R., Idle J. R. Debrisoquine metabolism and genetic predisposition to lung cancer. British Journal of Cancer 1989; 59: 686–687
   PubMed Web of Science ®Google Scholar
• Lin H. J., Han C. Y., Bernstein D. A., Hsiao W., Lin B. K., Hardy S. Ethnic distribution of the glutathione transferase M1–1 (GSTM1null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 1994; 15: 1077–1081
   PubMed Web of Science ®Google Scholar
• Liu L., Wang L. H. Correlation between lung prevalence and activities of aryl hydrocarbon hydroxylase and glutathione S-transferase in human lung tissues. Biomedical & Environmental Science 1988; 1: 277–282
   PubMedGoogle Scholar
• London S. J., Daly A. K., Fairbrother K. S., Holmes C, Carpenter C. L., Navidi W. C., Idle J. R. Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism. Cancer Research 1995; 55: 6035–6037
   PubMed Web of Science ®Google Scholar
• Lower G. M., Nilsson T., Nelson C E., Wolf H., Gamsky T. E., Bryan G. T. Nacetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Environmental Health Perspectives 1979; 29: 71–79, Preliminary results in Sweden and Denmark.
   PubMed Web of Science ®Google Scholar
• Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 586–586
   PubMed Web of Science ®Google Scholar
• Mannervik B. The isozymes of glutathione S-transferase. Advances in Enlymology 1985; 57: 357–417
   PubMedGoogle Scholar
• McLemore T. L., Martin R. R., Busbee D. L., Ritchie R. C., Springer R. R., Toppel K. L., Comtrell E. T. Aryl hydrocarbon hydroxylase activity in pulmonary macrophages and lymphocytes from lung cancer and non cancer patients. Cancer Research 1977; 37: 1175–1181
   PubMed Web of Science ®Google Scholar
• McLemore T. L., Martin R. R., Wray N. P., Cantrell E. T., Busbee D. L. Dissociation between aryl hydrocarbon hydroxylase activity in cultured pulmonary macrophages and blood lymphocytes from lung cancer patients. Cancer Research 1978; 38: 3805–3811
   PubMed Web of Science ®Google Scholar
• McLunore T. L., Martin R. R., Springer R. R., Wray N., Cantrell E. T., Busbee D. L. Aryl hydrocarbon hydroxylase activity in pulmonary alveolar macrophages and lymphocytes from lung cancer and non cancer patients: a correlation with family histories of cancer. Biochemical Genetics 1979; 17: 795–806
   PubMed Web of Science ®Google Scholar
• Meyer C. F., Zanger U. M., Grant D., Blume M. Genetic polymorphism of drug metabolism. Advances in Drug Research 1990; 19: 198
   Google Scholar
• Miller M. E., Cosgriff J. M. Acetyl phenotype in human bladder cancer. Journal of Urology 1983; 130: 65–66
   PubMed Web of Science ®Google Scholar
• Mokmsen S., Aagaaro J. N-acetyilransferase phenotyws in the urinary bladder carcinogenesis of a law-risk population. Carcinogmsis 1985; 6: 199–201
   PubMed Web of Science ®Google Scholar
• Nakach K., Iman K., Hayash S., Watanabe J., Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Research 1991; 51: 5177–5180
   PubMed Web of Science ®Google Scholar
• Nakachi K., Imai K., Hayashi S., Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibilty to lung cancer in relation to cigarette dose in a Japanese population. Cancer Research 1983; 53: 2994–2999
   Google Scholar
• Nakajima T., Elovaara E., Anttila S., Hirvonen A., Camus A. M., Hayes J. D., Kettere B., Vainio H. Expression and polymorphism of glutathioneStransferase in human lungs: risk factor in smoking-related cancer. Carcinogenesis 1995; 16: 707–711
   PubMed Web of Science ®Google Scholar
• Nazar-Stewart V., Motulsky A. G., Eaton D. L., White E., Hornung S. K., Leng Z. T., Stapleton P., Weiss N. S. The glutathione S-transferase μ polymorphism as a marker for susceptibility to lung carcinoma. Cancer Research 1993; 53: 2313–2318
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Gonzalez F. J. P450 genes: structure, evolution and regulation. Annual Review of Biochemistry 1987; 56: 945–993
   PubMed Web of Science ®Google Scholar
• Oda Y., Tanaka M., Naknish I. Relation between the occurrence of K-ras gene point mutations and genotypes of polymorphic N-acetyltransferase in human colorectal carcinomas. Carcinogenesis 1994; 15: 1365–1369
   PubMed Web of Science ®Google Scholar
• Petruzzelu S., Camus A. M., Carrozzi L., Ghelarducci L., Rindi M., Menconi G., Angem C. A., Ahotupa M., Hietanen E., Amo A., Saracci R., Bartsch H., Guntini C. Long-lasting effects of tobacco smoking on pulmonary drug-metabolizing enzyme: a case-control study on lung cancer patients. Cancer Research 1988; 48: 4695–4700
   PubMed Web of Science ®Google Scholar
• Philip P. A., Rogers H. J., Mills R. R., Rubens R. D., Cartwiight R. A. Acetylator status and its relationship to breast cancer and other diseases of the breast. European Journal of Cancer & Clinical Oncology 1987; 23: 1701–1706
   PubMedGoogle Scholar
• Philip P. A., Fitgerald D. L., Cartwright R. A., Peake M. D., Rogers H. J. Polymorphic N-acetylation capacity in lung cancer. Carcinogenesis 1988; 9: 491–493
   PubMed Web of Science ®Google Scholar
• Rebbeck T. R., Rosvoco E. A., Duggan D. J., Zhang J., Buetow K. H. Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer. Cancer Epidemiology, Biomarkers and Prevention 1994; 3: 511–514
   PubMed Web of Science ®Google Scholar
• Risch A., Wallace D. M. A., Bathers S., Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Human Molecular Genetics 1995; 4: 231–236
   PubMed Web of Science ®Google Scholar
• Roots I., Drakoulis N., Ploch M., Heinemeyer G., Loddendemper R., Minks T., Nitz M., Otte F., Koch M. Debrisoquine hydroxylation phenotype, acetylation phenotype, and AEO blood groups as genetic host factors of lung cancer risk. Klinische Wochenschrift 1988; 66: 87–97, suppl. XI
   PubMedGoogle Scholar
• Rothman N., Stewart W. F., Caporaso N. E., Hayes R. B. Misclassification of genetic susceptibility biomarkers: implication for case-control studies and crosspopulation comparison. Cancer Epidemiology, Biomarkers and Prevention 1993; 2: 299–303
   PubMed Web of Science ®Google Scholar
• Seidegard J., Pero R. W. The hereditary transmission of high glutathione transferase activity towards trans-stilbene oxide in human mononuclear leukocytes. Human Genetics 1985; 69: 66–48
   PubMed Web of Science ®Google Scholar
• Seidegard J., Pero R. W., Miller D. G., Beattie E. J. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis 1986; 7: 751–753
   PubMed Web of Science ®Google Scholar
• Seidegard J., Pero R. W., Markovitz M. M., Roush G., Miller D. G., Beatte E. J. Isoenzyme(sof glutathione transferase (class Muas a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis 1990; 11: 33–36
   PubMed Web of Science ®Google Scholar
• Seidegard J., De Pierre J., Birberg W., Pilotti A., Rero R. W. Characterization of soluble glutathione transferase activity in restin mononuclear leukocytes from human blood. Biochemistry and Pharmacology 1984; 33: 3053–3058
   PubMed Web of Science ®Google Scholar
• Shaw G. I., Falk R. T., DesIauriers J., Frame J. N., Nesbitt J. C., Passs H. I., Issaq H. J., Hoover R. N., Tucker M. A. Debrisoquine metabolism and lung cancer risk. Cancer Epidemiology, Biomarkers and Prevention 1995; 4: 41–48
   PubMed Web of Science ®Google Scholar
• Shibuta K., Nakashima T., Abe M., Mashimo M., Mori M., Ueo H., Akiyoshi T., Sugimachi K., Suzuki T. Molecular genotyping for N-acetylation polymorphism in Japanese patients with colorectal cancer. Cancer 1994; 74: 3108–3112
   PubMed Web of Science ®Google Scholar
• Shelds P. G., Caporaso N. E., Falk R. T., Sugimura H., Trivers G. E., Trump B. F., Hoover R. N., Weston A., Harris C. C. Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiology, Biomarkers and Prevention 1993; 2: 481–485
   PubMed Web of Science ®Google Scholar
• Sivaraman L., Leatham M. P., Yee J., Wilkens L. R., Lau A. F., Le Marchano L. CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Research 1994; 54: 3692–3695
   PubMed Web of Science ®Google Scholar
• Strange R. C., Matharoo B., Faulder G. C., Jones P., Cotton W., Elder J. B., Deakin M. The human glutathione S-transferase: a case-control study of the incidence of the GST10 phenotype in patients with adenocarcinoma. Carcinogenesis 1991; 12: 25–28
   PubMed Web of Science ®Google Scholar
• Sugimura H., Caporaso N. E., Shaw G. L., Mooali R. V., Gonzalez F. J., Hoover R. N., Resau J. H., Trump B. F., Weston A., Harris C. C. Human debrisoquine hydroxylase gene polymorphism in cancer patients and controls. Carcinogenesis 1990; 11: 1527–1530
   PubMed Web of Science ®Google Scholar
• Sugimara H., Suzuki I., Hamada G. S., Iwase T, Takahashi T., Nagura K., Iwata H., Watanabe S., Kino I., Tsugane S. Cytochrome P-450 1A1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil. Cancer Epidemiology, Biomarkers and Prevention 1994; 3: 145–148
   PubMed Web of Science ®Google Scholar
• Taiou E., Trachman J., Chen X., Toniolo P., Garte S. J. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Research 1995a; 55: 3757–3758
   PubMed Web of Science ®Google Scholar
• Taiou E., Crofts F., Trachman J., Demopoulos R., Toniolo P., Garte S. J. A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung. Cancer Research 1995b; 55: 472–473
   PubMed Web of Science ®Google Scholar
• Tefre T., Ryberg D., Haugen A., Nebert D. W., Skaug V., Brogger A., Borresen A. L. Human CYP1A1 (cytochrome P(1)450gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1991; 1: 20–5
   PubMedGoogle Scholar
• Tefre T., Daly A. K., Armstrong M., Leathart J. B. S., Idle J. R., Brogger A., Borresen A. cenotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharrnacogenetics 1994; 4: 47–57
   PubMed Web of Science ®Google Scholar
• Vatss K. P., Weber W. W. Structural heterogeneity of Caucasian Nacetyltransferase at the NAT1 gene locus. Archives of Biochemistry and Biophysics 1993; 301: 71–76
   PubMed Web of Science ®Google Scholar
• Warholm M., Guthenberg C., Mannervik B., von Bahr C. Purification of a new glutathione Stransferase (transferase μfrom human liver having high activity with benzo(a)pyrene-4, 5-oxide. Biochemical and Biophysical Research Communications 1981; 98: 512–519
   PubMed Web of Science ®Google Scholar
• Webster D. J.I., Flook D., Jenkins J., Hutchings A., Routledge P. A. Drug acetylation in breast cancer. British Journal of Cancer 1989; 60: 236–237
   PubMed Web of Science ®Google Scholar
• Wohlleb J. C., Hunter C. F., Buss B., Kadlubar F. F., Chu D. Z. J., Lang N. P. Aromatic amines acetyltransferase as a marker for colorectal cancer: environmental and demographic associations. International Journal of Cancer 1990; 46: 22–30
   PubMed Web of Science ®Google Scholar
• Wolf C. R. Cytochrome P450s: a multigene family involved in carcinogen metabolism. Trends in Genetics 1986; 2: 209–214
   Web of Science ®Google Scholar
• Wolf Dale C. R., Smith C. A., Gough A. C., Moss J. E., Valus K. A., Howard G., Carey F. J., Mills K., McNee W., Carmichael J., Spurr N. K. Relationship between debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992; 13: 1035–1038
   PubMed Web of Science ®Google Scholar
• Yoshkawa M., Arashidani K., Kawamoto T., Kooama Y. Aryl hydrocarbon hydroxylase acttvity in human lung tissue: in relation to cigarette smoking and lung cancer. Environmental Research 1994; 65: 1–11
   PubMed Web of Science ®Google Scholar
• Zhong S., Howe A. F., Ketterer B., Tanor J., Hayes J. D., Beckett G. J., Wathen C. G., Wolf C. R., Spurr N. K. Glutathione transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991; 12: 1553–1537
   Web of Science ®Google Scholar
• Zhong S., Wylle A. H., Barnes D., Wolf C. R., Spurr N. K. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 1993; 14: 1821–1824
   PubMed Web of Science ®Google Scholar